Major
Established
الوصف
Carbamazepine dramatically reduces aripiprazole plasma levels through potent CYP3A4 induction, potentially rendering antipsychotic treatment ineffective.
الآلية
Carbamazepine induces CYP3A4, the primary enzyme metabolizing aripiprazole, reducing aripiprazole AUC by approximately 70%.
الأهمية السريرية
Psychiatric relapse due to sub-therapeutic aripiprazole levels is a major risk; FDA labeling explicitly requires a dose doubling.
التدبير
Double aripiprazole dose when co-prescribed with carbamazepine per FDA label; monitor clinical response and reduce dose if carbamazepine is discontinued.